作者
Brandon L Adler, Catherine J Wang, Thanh-Lan Bui, Hannah M Schilperoort, April W Armstrong
发表日期
2019/6/1
来源
Seminars in arthritis and rheumatism
卷号
48
期号
6
页码范围
1093-1104
出版商
WB Saunders
简介
Background
Though anti-tumor necrosis factor agents (anti-TNFs) have been recommended as third-line therapy for sarcoidosis, an up-to-date systematic synthesis of their efficacy and safety is lacking.
Objectives
To systematically review the literature to characterize the efficacy and safety of anti-TNFs in sarcoidosis.
Settings
All countries and treatment settings were included.
Methods
We searched MEDLINE, EMBASE, CINAHL, Web of Science, ClinicalTrials.gov, Cochrane Library, and Google Scholar from inception to November 27, 2017. Studies of five or more cases of sarcoidosis treated with anti-TNFs were included. Descriptive statistics were performed.
Results
Sixty-five studies (including five randomized controlled trials [RCTs]) were identified, comprising 1525 patients. For pulmonary sarcoidosis, one RCT found infliximab (IFX) significantly improved vital capacity vs. placebo; a second detected no difference. In …
学术搜索中的文章
BL Adler, CJ Wang, TL Bui, HM Schilperoort… - Seminars in arthritis and rheumatism, 2019